German Funds Face Deficit For 1996

3 September 1995

german public-sector health funds face a 3 billion Deutschemark ($2.03 billion) deficit in 1996, says the federation of industrial health funds, after a "drastic increase" in health spending. Federation managing director Wolfgang Schmeinck says higher premiums will probably be needed in 1996.

Fund spending per member rose 6% in the west and 16.5% in the east in first-half 1995, against a 2% rise in western basic wages and an eastern rise of 5.5%. drug spending rose 9.5% in the west, which Mr Schmeinck says is causing concern. Eastern drug spending rose 23%.

However, hospital spending is said to be the main reason for the rise in fund spending. Eckart Fiedler, director of the federation of supplementary funds, says these funds show first-half 1995 deficits of 750 million marks in western germany and 209 million marks in the east, compared to first-half 1994 surpluses of 782 million marks in the west and 92 million marks in the east. Hospital spending rose 6.2% in the west and 14.8% in the east in first-half 1995, accelerating in the second quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight